Talphera | 10-Q: FY2025 Q3 Revenue: USD 1 K

Revenue: As of FY2025 Q3, the actual value is USD 1 K.

EPS: As of FY2025 Q3, the actual value is USD -0.11, meeting the estimate of USD -0.11.

EBIT: As of FY2025 Q3, the actual value is USD -3.503 M.

Financial Metrics by Segment

Segment Revenue

• Revenue for the three months ended September 30, 2025: $1,000
• Revenue for the nine months ended September 30, 2025: $28,000

Operational Metrics

• Net Loss:
  • Three months ended September 30, 2025: - $4,436,000
  • Nine months ended September 30, 2025: - $10,518,000
• Research and Development Expenses:
  • Three months ended September 30, 2025: $1,803,000
  • Nine months ended September 30, 2025: $4,472,000
• Selling, General and Administrative Expenses:
  • Three months ended September 30, 2025: $1,620,000
  • Nine months ended September 30, 2025: $5,587,000
• Total Operating Costs and Expenses:
  • Three months ended September 30, 2025: $3,423,000
  • Nine months ended September 30, 2025: $10,059,000
• Loss from Operations:
  • Three months ended September 30, 2025: - $3,422,000
  • Nine months ended September 30, 2025: - $10,031,000
• Other (Expense) Income, Net:
  • Three months ended September 30, 2025: - $1,014,000
  • Nine months ended September 30, 2025: - $560,000

Cash Flow

• Net Cash Used in Operating Activities:
  • Nine months ended September 30, 2025: - $8,928,000
• Net Cash (Used in) Provided by Investing Activities:
  • Nine months ended September 30, 2025: - $17,815,000
• Net Cash Provided by Financing Activities:
  • Nine months ended September 30, 2025: $21,337,000

Unique Metrics

• Warrant Liability:
  • September 30, 2025: $1,854,000
  • December 31, 2024: $1,061,000
• Liability Related to the Sale of Future Payments:
  • September 30, 2025: $6,499,000
  • December 31, 2024: $6,527,000

Future Outlook and Strategy

• Core Business Focus:
  • Talphera, Inc. is focused on developing and commercializing innovative therapies for use in medically supervised settings, with a primary focus on Niyad, a regional anticoagulant for the dialysis circuit, and LTX-608, a nafamostat formulation for direct IV infusion for various indications.
  • The company plans to expand its portfolio to include additional acute care therapies for use in medically supervised settings.
• Non-Core Business:
  • The company may seek to raise additional capital through public or private equity offerings, debt securities, a new debt facility, or entering into product development, license, or distribution agreements with third parties.
  • Talphera, Inc. is also considering divesting any of its remaining product candidates to fund its planned operations.